GYRE (GYRE) director receives stock options for 40,000 common shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
GYRE THERAPEUTICS, INC. director David M. Epstein received a grant of stock options to acquire 40,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on June 10, 2036.
The award was made as a compensation-related grant, with no cash purchase by the insider at grant. According to the terms, the options will vest in 12 equal monthly installments through June 10, 2027, so long as Epstein continues to provide service to the company through each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Epstein David M.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 40,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 40,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 40,000 shares
Exercise price: $5.95 per share
Expiration date: June 10, 2036
+2 more
5 metrics
Option grant size
40,000 shares
Stock Option (Right to Buy) awarded to director
Exercise price
$5.95 per share
Conversion or exercise price of options
Expiration date
June 10, 2036
Option term end date
Shares underlying options
40,000 shares
Underlying common stock covered by option
Vesting period
12 monthly installments
Through June 10, 2027, subject to continued service
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "5.9500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"which will vest in 12 equal monthly installments through June 10, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-10T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: "Common Stock""
FAQ
What did GYRE director David M. Epstein report on this Form 4?
David M. Epstein reported receiving a grant of stock options for 40,000 shares of GYRE common stock. These options are a compensation award, not an open-market stock purchase or sale, and give him the right to buy shares at a fixed exercise price.
What is the exercise price and expiration date of Epstein’s GYRE options?
The stock options have an exercise price of $5.95 per share and expire on June 10, 2036. Epstein can only benefit economically if GYRE’s stock trades above this price before expiration.
How do the vesting terms work for Epstein’s GYRE option award?
The 40,000-share option grant vests in 12 equal monthly installments through June 10, 2027. Vesting is contingent on Epstein’s continued service to GYRE for each monthly vesting date during this period.